Ozanimod hydrochloride NEW
| Price | $42 | $98 | $147 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-12-10 |
Product Details
| Product Name: Ozanimod hydrochloride | CAS No.: 1618636-37-5 |
| Purity: 99.81% | Supply Ability: 10g |
| Release date: 2025/12/10 |
Product Introduction
Bioactivity
| Name | Ozanimod hydrochloride |
| Description | Ozanimod hydrochloride (RPC-1063 hydrochloride) is an orally available, selective and potent sphingosine 1-phosphate (S1P) receptor modulator that shows high affinity for S1P1 and S1P5.Ozanimod has potential anticancer activity and can be used in the study of multiple sclerosis (MS), ulcerative multiple sclerosis (UMS), and other diseases. (MS), ulcerative colitis, coronavirus infections and myelodysplasia. |
| In vitro | Ozanimod hydrochloride, as a sphingosine-1-phosphate (S1P) receptor modulator, selectively binds with high affinity to S1P receptor subtypes 1 (S1P1) and S1P5[1]. |
| In vivo | In the experimental autoimmune encephalomyelitis (EAE) model, Ozanimod hydrochloride (0.05, 0.2, or 1 mg/kg; oral gavage; once daily; for 14 consecutive days) alleviated weight loss, with significantly reduced terminal disease scores observed in the 0.2 and 1 mg/kg dose groups. Moreover, cell counts were significantly reduced in all dose groups[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (11.34 mM), Sonication is recommended. DMSO : 150 mg/mL (340.2 mM), Sonication is recommended. |
| Keywords | S1PReceptor | S1P Receptor | S1P |
| Inhibitors Related | Fingolimod hydrochloride | Tyloxapol | Sphingosine-1-phosphate | ASP-4058 | CAY10444 | Ki16198 | Siponimod | CYM5181 | Poloxamer 407 | MP-A08 | S1PR1 modulator 1 | Ozanimod |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/10mg |
VIP2Y
|
Moxin Chemicals
|
2025-05-15 | |
| $600.00/1g |
Wuhan Nutra Biotechnology Co.,Ltd
|
2021-05-23 | ||
| $2.00/100kg |
VIP1Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2025-06-19 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY